SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. – Trademark Portfolio
Entity Type: 03
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ZS.
Fanlou Road South of Shanxian Development Zone,
Heze City 274300 Shandong Province
Showing of trademarks Trademarks
Trademark Classifications
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. have?
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.
What trademark classes does SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. file in?
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 3 (Cosmetics & Cleaning). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.'s most well-known trademarks?
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.'s registered trademark portfolio includes well-known marks such as ZS. These are among 1 currently registered trademark in the portfolio.
What is SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.'s trademark registration success rate?
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.